232 related articles for article (PubMed ID: 17184589)
21. Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells.
Opalinska JB; Machalinski B; Ratajczak J; Ratajczak MZ; Gewirtz AM
Clin Cancer Res; 2005 Jul; 11(13):4948-54. PubMed ID: 16000594
[TBL] [Abstract][Full Text] [Related]
22. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
23. [Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression].
Ma XX; Wang C; Wei J; Qin YW; Yan SK; Gao YR; Cai Q
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):359-62. PubMed ID: 16185484
[TBL] [Abstract][Full Text] [Related]
24. Photodynamic treatment (ALA-PDT) suppresses the expression of the oncogenic Bcr-Abl kinase and affects the cytoskeleton organization in K562 cells.
Pluskalová M; Peslová G; Grebenová D; Halada P; Hrkal Z
J Photochem Photobiol B; 2006 Jun; 83(3):205-12. PubMed ID: 16495075
[TBL] [Abstract][Full Text] [Related]
25. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
[TBL] [Abstract][Full Text] [Related]
26. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
27. [Inhibitory effect of 4-chlorobenzoyl berbamine on imatinib-resistant K562 cells in vitro and in vivo].
Zhang YF; Xu GB; Gan YC; Xu XH; Xu RZ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1997-2001. PubMed ID: 22200699
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression.
Notarbartolo M; Poma P; Perri D; Dusonchet L; Cervello M; D'Alessandro N
Cancer Lett; 2005 Jun; 224(1):53-65. PubMed ID: 15911101
[TBL] [Abstract][Full Text] [Related]
29. [Inhibition of curcumin on histone deacetylase and expression promotion of P21 (WAF1/CIP1) in HepG2 cells].
Lv BH; Zhang L; Zhu CC; Liu J
Zhongguo Zhong Yao Za Zhi; 2007 Oct; 32(19):2051-5. PubMed ID: 18161303
[TBL] [Abstract][Full Text] [Related]
30. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
31. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
[TBL] [Abstract][Full Text] [Related]
32. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
33. [Effect of phenylhexyl isothiocyanate on drug-resistance to imatinib in K562/G01 cell line].
Wu RJ; Huang YQ; Ma XD
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):149-52. PubMed ID: 23611223
[TBL] [Abstract][Full Text] [Related]
34. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Withey JM; Harvey AJ; Crompton MR
Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
[TBL] [Abstract][Full Text] [Related]
35. Curcumin inhibits WT1 gene expression in human leukemic K562 cells.
Anuchapreeda S; Thanarattanakorn P; Sittipreechacharn S; Chanarat P; Limtrakul P
Acta Pharmacol Sin; 2006 Mar; 27(3):360-6. PubMed ID: 16490174
[TBL] [Abstract][Full Text] [Related]
36. Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy.
Acharya S; Sahoo SK
Biomaterials; 2011 Aug; 32(24):5643-62. PubMed ID: 21600647
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-κB signaling pathways.
Liao S; Xia J; Chen Z; Zhang S; Ahmad A; Miele L; Sarkar FH; Wang Z
J Cell Biochem; 2011 Apr; 112(4):1055-65. PubMed ID: 21308734
[TBL] [Abstract][Full Text] [Related]
38. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
39. Phosphorothioate-capped antisense oligonucleotides to Ras GAP inhibit cell proliferation and trigger apoptosis but fail to downregulate GAP gene expression.
White JR; Gordon-Smith EC; Rutherford TR
Biochem Biophys Res Commun; 1996 Oct; 227(1):118-24. PubMed ID: 8858112
[TBL] [Abstract][Full Text] [Related]
40. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]